Epiomic Epidemiology Series: Retinal Vein Occlusion Forecast in 18 Major Markets 2018–2028

January 2018 | 72 pages | ID: E2B6A3A580CEN
Black Swan Analysis limited

Abstracts

Black Swan Analysis Epiomic Epidemiology Forecast Report on Retinal Vein Occlusion in 18 Major Markets

Retinal vein occlusion (RVO) is a common vascular disorder of the retina and the second-most common cause of vision loss worldwide after diabetic retinopathy. Its classification and pathogenesis have not yet been fully established, and even though a range of therapeutic approaches to RVO are available, sequelae of the disorder may still lead to a significant degree of vision loss by various mechanisms.

This report provides the current prevalent population for RVO across 18 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. In addition to the current prevalence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, RVO subtypes, several features of RVO patients, as well as the main comorbidities of the disease have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities of RVO include:

• Cardiovascular diseases (mainly hypertension)
• Diabetes mellitus
• Hypertension
• Glaucoma

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world-class sources that deliver the most up-to-date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Ability to quantify patient populations in global RVO market to target the development of future products, pricing strategies and launch plans.
• Further insight into the prevalence of the subdivided types of RVO and identification of patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Better understanding of the impact of specific co-morbid conditions on the prevalent population of RVO patients.
• Identification of RVO patient sub-populations that require treatment.
• Better understanding of the specific markets that have the largest number of RVO patients.

Contents

INTRODUCTION

CAUSE OF THE DISEASE

RISK FACTORS & PREVENTION

DIAGNOSIS OF THE DISEASE

VARIATION BY GEOGRAPHY/ETHNICITY

DISEASE PROGNOSIS & CLINICAL COURSE

KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE

METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS

TOP-LINE PREVALENCE FOR RETINAL VEIN OCCLUSION

FEATURES OF RETINAL VEIN OCCLUSION PATIENTS

CENTRAL RVO

BRANCH RVO

ABBREVIATIONS USED IN THE REPORT

OTHER BLACK SWAN SERVICES & SOLUTIONS

REPORTS & PUBLICATIONS

ONLINE EPIDEMIOLOGY DATABASES

ONLINE PHARMACEUTICAL PRICING DATABASE

REFERENCES

APPENDIX

List Of Tables

LIST OF TABLES AND FIGURES

Table 1. Prevalence of retinal vein occlusion, total (000s)
Table 2. Prevalence of retinal vein occlusion, males (000s)
Table 3. Prevalence of retinal vein occlusion, females (000s)
Table 4. Patients with retinal vein occlusion by type of disease, total (000s)
Table 5. Patients with retinal vein occlusion by main occlusion location, total (000s)
Table 6. Patients with CRVO by main aetiology, total (000s)
Table 7. CRVO patients with glaucoma, total (000s)
Table 8. CRVO patients by type of glaucoma, total (000s)
Table 9. CRVO patients with macular oedema, total (000s)
Table 10. CRVO patients with pseudoexfoliation, total (000s)
Table 11. CRVO patients with diabetes, total (000s)
Table 12. CRVO patients with hypertension, total (000s)
Table 13. CRVO patients with coronary artery disease, total (000s)
Table 14. CRVO patients with hypercholesterolaemia, total (000s)
Table 15. Patients with BRVO by main type, total (000s)
Table 16. Patients with BRVO by macular status at diagnosis, total (000s)
Table 17. BRVO patients with glaucoma, total (000s)
Table 18. BRVO patients by type of glaucoma, total (000s)
Table 19. BRVO patients with macular oedema, total (000s)
Table 20. BRVO patients with pseudoexfoliation, total (000s)
Table 21. BRVO patients with dense macular haemorrhage, total (000s)
Table 22. BRVO patients with diabetes, total (000s)
Table 23. BRVO patients with hypertension, total (000s)
Table 24. BRVO patients with coronary artery disease, total (000s)
Table 25. BRVO patients with hypercholesterolaemia, total (000s)
Table 26. Abbreviations and acronyms used in the report
Table 27. USA prevalence of retinal vein occlusion by 5-yr age cohort, males (000s)
Table 28. USA prevalence of retinal vein occlusion by 5-yr age cohort, females (000s)
Table 29. Canada prevalence of retinal vein occlusion by 5-yr age cohort, males (000s)
Table 30. Canada prevalence of retinal vein occlusion by 5-yr age cohort, females (000s)
Table 31. France prevalence of retinal vein occlusion by 5-yr age cohort, males (000s)
Table 32. France prevalence of retinal vein occlusion by 5-yr age cohort, females (000s)
Table 33. Germany prevalence of retinal vein occlusion by 5-yr age cohort, males (000s)
Table 34. Germany prevalence of retinal vein occlusion by 5-yr age cohort, females (000s)
Table 35. Italy prevalence of retinal vein occlusion by 5-yr age cohort, males (000s)
Table 36. Italy prevalence of retinal vein occlusion by 5-yr age cohort, females (000s)
Table 37. Spain prevalence of retinal vein occlusion by 5-yr age cohort, males (000s)
Table 38. Spain prevalence of retinal vein occlusion by 5-yr age cohort, females (000s)
Table 39. UK prevalence of retinal vein occlusion by 5-yr age cohort, males (000s)
Table 40. UK prevalence of retinal vein occlusion by 5-yr age cohort, females (000s)
Table 41. Poland prevalence of retinal vein occlusion by 5-yr age cohort, males (000s)
Table 42. Poland prevalence of retinal vein occlusion by 5-yr age cohort, females (000s)
Table 43. Netherlands prevalence of retinal vein occlusion by 5-yr age cohort, males (000s)
Table 44. Netherlands prevalence of retinal vein occlusion by 5-yr age cohort, females (000s)
Table 45. Turkey prevalence of retinal vein occlusion by 5-yr age cohort, males (000s)
Table 46. Turkey prevalence of retinal vein occlusion by 5-yr age cohort, females (000s)
Table 47. Japan prevalence of retinal vein occlusion by 5-yr age cohort, males (000s)
Table 48. Japan prevalence of retinal vein occlusion by 5-yr age cohort, females (000s)
Table 49. China prevalence of retinal vein occlusion by 5-yr age cohort, males (000s)
Table 50. China prevalence of retinal vein occlusion by 5-yr age cohort, females (000s)
Table 51. South Korea prevalence of retinal vein occlusion by 5-yr age cohort, males (000s)
Table 52. South Korea prevalence of retinal vein occlusion by 5-yr age cohort, females (000s)
Table 53. India prevalence of retinal vein occlusion by 5-yr age cohort, males (000s)
Table 54. India prevalence of retinal vein occlusion by 5-yr age cohort, females (000s)
Table 55. Australia prevalence of retinal vein occlusion by 5-yr age cohort, males (000s)
Table 56. Australia prevalence of retinal vein occlusion by 5-yr age cohort, females (000s)
Table 57. Brazil prevalence of retinal vein occlusion by 5-yr age cohort, males (000s)
Table 58. Brazil prevalence of retinal vein occlusion by 5-yr age cohort, females (000s)
Table 59. Mexico prevalence of retinal vein occlusion by 5-yr age cohort, males (000s)
Table 60. Mexico prevalence of retinal vein occlusion by 5-yr age cohort, females (000s)
Table 61. Argentina prevalence of retinal vein occlusion by 5-yr age cohort, males (000s)
Table 62. Argentina prevalence of retinal vein occlusion by 5-yr age cohort, females (000s)